The cannabis cardiovascular problem: JAMA, JACC, and what the studies keep finding
JAMA Cardiology: endothelial dysfunction from smokers AND edible users, comparable to tobacco smokers. JACC: under-50 users 6.2x more likely to have a heart attack, 4.3x more likely to have a stroke. Meta-analysis: 2x cardiovascular death risk. The evidence is substantial, growing, and pointing in a consistent direction — and it deserves honest engagement, not dismissal.
Over the past three years, a consistent pattern has emerged in cardiovascular cannabis research. Published in JAMA Cardiology, the Journal of the American College of Cardiology, and the Journal of the American Heart Association, the studies point in the same direction: cannabis use is associated with measurably elevated cardiovascular risk, including heart attack, stroke, and cardiovascular mortality — and the finding holds across delivery methods, not just smoking.
This is not a politically convenient finding for cannabis advocates, nor for the rapidly expanding beverage and edibles market. But the evidence is not going away, and it deserves the same level of serious engagement as the evidence on tobacco, alcohol, and other categories of consumption product.
Here is what the literature actually says.
JACC: under-50 heart attack risk
A large multicenter retrospective study published in JACC: Advances examined cannabis use and cardiovascular outcomes in adults under 50 — a population generally considered low risk for cardiovascular events under normal circumstances.
The findings:
- Cannabis users under 50 were 6.2 times more likely to experience a heart attack (myocardial infarction) than non-users
- 4.3 times more likely to experience an ischemic stroke
- Roughly 2 times more likely to experience heart failure
These risk ratios are, by the standards of cardiovascular epidemiology, substantial. Even accounting for confounders typically associated with cannabis use (tobacco co-use, alcohol, socioeconomic factors, pre-existing conditions), the effect size is large enough that researchers have consistently described the association as unlikely to be purely confounded.
The study was a retrospective analysis, which means it identifies associations rather than proving causation. The authors and peer reviewers were explicit about this limitation. But the magnitude of the association — at more than six times the baseline risk for heart attacks in a population typically protected by age — is the single largest cardiovascular signal identified in modern cannabis research.
JAMA Cardiology: endothelial dysfunction across delivery methods
Perhaps the most methodologically interesting recent study came from researchers at UC San Francisco and published in JAMA Cardiology. The study examined endothelial function — the health and responsiveness of the blood vessel lining, a well-established marker of cardiovascular risk — in three groups:
- Chronic marijuana smokers
- THC edible users
- Non-users
The finding was striking: both smokers and edible users showed reduced endothelial function comparable to tobacco smokers, when compared to non-users.
This result matters because it rules out one of the most common defenses of edible and beverage consumption: the argument that cardiovascular risk is attributable to combustion products (smoke, particulates, carbon monoxide) rather than to THC itself. If edibles produce comparable endothelial dysfunction to smoking, the mechanism appears to be at least partially independent of combustion.
The study was observational, the sample sizes were modest, and the authors were careful to note that the findings require confirmation in larger trials. But the direction — edibles showing effects comparable to smoking — contradicts a reassuring assumption about non-combusted delivery methods that has been widely adopted in cannabis product marketing.
The meta-analysis: pooling the evidence
A meta-analysis published in a major cardiology journal pooled data across multiple cannabis cardiovascular studies and produced pooled risk ratios:
- Acute coronary syndrome (heart attack risk): RR 1.29 (95% CI 1.05–1.59)
- Stroke: RR 1.20 (95% CI 1.13–1.26)
- Cardiovascular death: RR 2.10 (95% CI 1.29–3.42)
These are smaller risk ratios than the JACC under-50 numbers because the meta-analysis pooled broader populations (including older adults with significant baseline cardiovascular risk, where cannabis's marginal contribution is proportionally smaller).
The confidence intervals all exclude 1.0, meaning the findings are statistically significant. The cardiovascular death number — roughly double the risk among cannabis users — is the most consequential single finding in the field.
The countervailing studies
Not every cannabis cardiovascular study has found significant risk elevation. A study in PMC examining cannabis smoking among older military veterans with pre-existing coronary artery disease found no significant association between cannabis use and cardiovascular events in that specific population.
This kind of mixed finding is typical in epidemiological research, and it suggests several things:
- Risk may vary by population. Cannabis's cardiovascular impact may be more pronounced in younger, otherwise healthy users than in older adults with already-elevated baseline risk.
- Confounding is real. Some earlier studies have struggled to fully separate cannabis effects from tobacco co-use, which remains common among cannabis users.
- Effect sizes depend on methodology. Retrospective chart reviews, prospective cohorts, and mechanistic studies will produce different magnitudes.
The fairest read of the literature as of April 2026: the overall signal points to elevated cardiovascular risk, with the strongest evidence in younger adults, and with the mechanism potentially involving direct THC effects on the endothelium rather than solely combustion byproducts.
What this does not mean
The research does not support, and is not generally used to support, any of the following claims:
- That cannabis is more cardiovascularly dangerous than tobacco (it is not, by most measures)
- That cannabis should be re-criminalized (the evidence does not support recriminalization any more than alcohol evidence supports re-prohibition)
- That medical cannabis for specific indications is inappropriate (the risk-benefit calculation is indication-specific)
- That occasional use carries the same risk as chronic heavy use (the available evidence suggests dose-response relationships)
What the research does support is a case for informed consumer awareness and clinical screening in populations where cardiovascular risk is already elevated — particularly younger adults with family history of early cardiovascular events.
The policy implications
Cardiovascular evidence rarely moves drug policy directly. Tobacco remains legal and widely available despite overwhelming evidence of far greater cardiovascular harm. Alcohol remains the single most cardiovascularly damaging legal substance consumed by Americans. The notion that cardiovascular risk should determine legal status is not a standard this country applies to any other consumer category.
What the cardiovascular evidence does support is:
- Product labeling that includes cardiovascular risk information, particularly for higher-dose products
- Medical cannabis screening that includes cardiovascular risk assessment
- FDA regulatory posture that treats cannabinoids as pharmacologically active compounds requiring risk-benefit analysis rather than as inert wellness products
- Marketing restrictions on unsupported health claims — particularly "safer than alcohol" framing that the endothelial evidence complicates
None of these are incompatible with federal rescheduling, state adult-use legalization, or the hemp beverage industry's expansion. They are compatible with the normal framework applied to every other legal consumer product with associated health risks.
The bottom line
The cardiovascular evidence on cannabis is substantial, growing, and pointing in a consistent direction. It does not justify recriminalization. It does not justify the suspension of medical cannabis programs. It does not justify panic.
It does justify the same honest, evidence-based public health posture this country applies — or should apply — to every other widely consumed substance with measurable cardiovascular impact. Cannabis-industry marketing that implies "safer than" framing without engaging the emerging evidence is, at this point, doing a disservice to both consumers and the industry's long-term credibility.
The plant is not tobacco. It is also not an inert wellness product. The research will continue, the evidence will refine, and serious advocates for cannabis — medical, recreational, and industrial — are best served by engaging the cardiovascular literature rather than discounting it.